Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

OBJECTIVE: In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Blonde, Lawrence, Rosenstock, Julio, Frias, Juan, Birkenfeld, Andreas L., Niemoeller, Elisabeth, Souhami, Elisabeth, Ji, Chen, Del Prato, Stefano, Aroda, Vanita R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896258/
https://www.ncbi.nlm.nih.gov/pubmed/33468520
http://dx.doi.org/10.2337/dc20-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896258/
https://www.ncbi.nlm.nih.gov/pubmed/33468520
http://dx.doi.org/10.2337/dc20-2023

Ejemplares similares